Skip to main content
Equibles

NGEN · Nervgen Pharma Corp.

Track NGEN — free

Use NGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.50 -0.04 (-2.42%)
Rebalance outlook locked
Market Cap
$165.58M
Shares
107.52M
Volume · Oct 21 297.52K Avg daily vol (3M) 495.03K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.50 Open$1.54 Day$1.50–1.55 52W close$1.50–5.97 Avg vol 30d468K Short int5.8M · 5.4% float · 11.3d Short vol59% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-49.7%
Trailing year
Short interest
5.4%
Latest settlement · 11.3 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −50%
below
Price vs 50-day avg −22%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −59%
trailing
YTD return −73%
this year
Relative strength −66%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
7 of 64 funds reported for Sep 30 · net +5.9K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.42% of float · ▲ +6.2% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
64 holders — near 4-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −75%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−50% Bearish
Price vs 50-day avg
−22% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
7 of 64 funds reported for Sep 30 · net +5.9K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.42% of float · ▲ +6.2% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
64 holders — near 4-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $6
vs 200-day avg -50% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NGEN
Nervgen Pharma Corp.
this stock
$165.58M -73.2% — — 5.4%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +15.7% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $96.65B +733.5% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.4% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.22B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
65
% held
11.4%
Reported
7 of 64
Top holder
Empery Asset Management,…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
5.8M
Days to cover
11.3d
Change
+342.2K sh
View
Short Volume
Short vol %
59%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
3.4K
Value
$6.6K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
49.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
40-F/A
Filed
Oct 16, 2026
This year
17

NervGen Pharma Corp. filed an amended and restated MD&A restating 2025 and 2024 financials due to a material weakness in internal controls. During 2025, NVG-291 met its primary endpoint in the CONNECT SCI Study, and the company completed a US$10,049,915 private placement.

View
Exempt Offerings
Offering
$1.1M
Filed
Dec 14, 2021
View

Performance

5D 20D 120D MTD YTD
NGEN -4.2% -23.5% -58.7% -21.5% -73.2%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY -4.6% -24.2% -66.3% -22.8% -86.6%
Key facts CIK 1751912 CUSIP 64082X203 13F (30d) 8 filings 8 filers Visit website Investor relations